CytoDyn (OTCMKTS:CYDY) has been assigned a $2.00 price target by stock analysts at HC Wainwright in a research note issued to investors on Friday. The brokerage presently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s price target would suggest a potential upside of 222.58% from the stock’s previous close.

CytoDyn stock opened at $0.62 on Friday. CytoDyn has a 12 month low of $0.40 and a 12 month high of $0.84. The company has a market capitalization of $148.45 million, a PE ratio of -2.14 and a beta of 0.33.

CytoDyn (OTCMKTS:CYDY) last posted its earnings results on Thursday, August 2nd. The biotechnology company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.06) by $0.02. sell-side analysts expect that CytoDyn will post -0.21 EPS for the current fiscal year.

CytoDyn Company Profile

CytoDyn Inc, a clinical-stage biotechnology company, focuses on the clinical development and commercialization of humanized monoclonal antibodies for the treatment and prevention of human immunodeficiency virus (HIV) infection. Its lead product under development for HIV infection include PRO 140, a therapeutic anti-viral agent, which is in Phase IIb treatment substitution trial, Phase IIb extension study, Phase IIb/III pivotal trial, and Phase IIb/III investigative trial for HIV; and Phase II trial for graft-versus-host disease.

Further Reading: What are the Benefits of Index Funds?

Receive News & Ratings for CytoDyn Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytoDyn and related companies with MarketBeat.com's FREE daily email newsletter.